期刊文献+

乳腺癌细胞NK细胞活化性配体表达和CIK细胞杀伤敏感性研究 被引量:2

Research on Ligand Expression of NK Cell Activation in Breast Cancer Cells and Sensitivity of CIK Cells
下载PDF
导出
摘要 目的研究乳腺癌细胞系MCF-7和MDA-MB-231细胞NK细胞活化性配体表达和细胞因子诱导的杀伤细胞(CIK)杀伤敏感性。方法采用流式细胞术检测MCF-7和MDA-MB-231细胞表面MICA、MICB、CD155和CD112的表达,PBMC在体外经γ-干扰素(IFN-γ),CD3抗体和IL-2诱导扩增为CIK细胞,乳酸脱氢酶释放法检测CIK细胞对MCF-7和MDA-MB-231细胞的杀伤活性。结果 MICA、MICB、CD155和CD112在MCF-7细胞表面的表达水平均明显高于MDA-MB-231细胞(P<0.01);培养15 d后,CIK细胞中CD3+CD56+细胞百分率显著增高(P<0.01);效靶比20:1时,CIK细胞对MDA-MB-231细胞的杀伤率高于其对MCF-7细胞的杀伤率,差异显著(P<0.01)。结论 CIK细胞对MCF-7和MDA-MB-231的杀伤活性不依赖于NK细胞活化性配体分子MICA、MICB、CD155和CD112的高表达;CIK过继免疫细胞治疗可能成为三阴乳腺癌的有效治疗手段。 Objective To study the ligand expressions of NK cell( nature killer cell) activation in MCF-7 and MDA-MB-231 cells in breast carcinoma cell line and sensitivity of CIK( cytokine-induced killer) cells. Methods The expressions of MICA,MICB,CD155 and CD112 on MCF-7 and MDA-MB-231 cells were detected by flow cytometry.CIK cells were obtained by the sequential ex vivo expansion of peripheral blood mononuclear cells( PBMC) with interferon-gamma( IFN-γ),and anti-CD3 antibody and recombinant human interleukin( IL)-2. The cytotoxicity of CIK cells against MCF-7 and MDA-MB-231 cells were detected by lactate dehydrogenase( LDH) release assay. Results The expressions of MICA,MICB,CD155 and CD112 on MCF-7 cells were significantly higher than those on MDA-MB-231 cells( P〈0. 01); after 15 d of ex vivo expansion,the percentage of CD3 + CD56 + cell increased significantly( P〈0. 01);at E: T ratios of 20: 1,the cytotoxicity of CIK cells against MDA-MB-231 was significantly higher than that against MCF-7( P〈0. 01). Conclusion The cytotoxicity of CIK cells against MCF-7 and MDA-MB-231 cells is independent of overexpressions of MICA,MICB,CD155 and CD112. CIK adoptive immunity of cell therapy may be an effective approach for treatment of triple-negative breast cancer.
出处 《解放军医药杂志》 CAS 2015年第1期44-47,共4页 Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金 辽宁省自然科学基金(2013020188)
关键词 乳腺肿瘤 细胞系 肿瘤 细胞因子诱导杀伤细胞 Breast neoplasms Cell line tumor Cytokine-induced killer cells
  • 相关文献

参考文献25

  • 1Liu L Y, Wang F, Yu L X, et al. Breast cancer aware- ness among women in Eastern China: a cross-sectional study [ J ] BMC Public Health, 2014,14 : 1004-1011.
  • 2Schmidt-Wolf I G, Negrin R S, Kiem H P, et al. Use of a SCID mouse/human lymphoma model to evaluate cyto- kine-induced killer cells with potent antitumor cell activity [J].J Exp Med, 1991,174(1) :139-149.
  • 3Zhang J, Zhu L, Wei J, et al. The effects of cytokine-in- duced killer cells for the treatment of patients with solid tumors: a elinical retrospective study [ J ]. J Cancer Res Clin Oncol, 2012,138(6) :1057-1062.
  • 4Jiang J, Wu C, Lu B. Cytokine-induced killer cells pro- mote antitumor immunity[ J]. J Transl Med, 2013,11:83-91.
  • 5Verneris M R, Karami M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and ex- panded CD8 + T cells [ J ]. Blood, 2004,103 ( 8 ) : 3065- 3072.
  • 6Huang B, Sikorski R, Sampath P, et al. Modulation of NKG2D ligand cell surface expression enhances immune cell therapy of cancer [ J ]. J Immunother, 2011,34 ( 3 ) : 289-296.
  • 7Chen Y, Lin G, Guo Z Q, et al. Effects of MICA expres- sion on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy [ J ]. PLoS One, 2013,8 ( 7 ) : e69044.
  • 8Pievani A, Borleri G, Pende D, et al. Dual-functional capability of CD3 + CD56 + CIK ceils, a T-cell subset that acquires NK function and retains TCR-mediated spe- cific cytotoxicity [ J ]. Blood, 2011,118 ( 12 ) :3301-3310.
  • 9Bauer S, Groh V, Wu J, et al. Activation of NK ceils and T cells by NKG2D, a receptor for stress-inducible MICA [ J ] Science, 1999,285 ( 5428 ) :727-729.
  • 10Zafirova B, Wensveen F M, Gulin M, et al. Regulation of immune cell function and differentiation by the NKG2D receptor[J]. Cell Mol Life Sci, 2011,68(21):3519- 3529.

二级参考文献29

  • 1曹建平,姜志明,张晓晨,蔺迪,陈伟,孙英慧,马东初.CIK在无血清培养体系中的增殖、表型变化和抗肿瘤活性[J].细胞与分子免疫学杂志,2005,21(5):583-586. 被引量:12
  • 2万崇华,杨铮,孟琼,汤学良,卢玉波,邹天宁,张冬梅.乳腺癌患者生命质量测定量表QLQ-BR53中文版的应用评价[J].肿瘤,2006,26(2):184-187. 被引量:73
  • 3Smith RA,Cokkinides V,Brooks D,et al.Cancer screening in the United States,2011:A review of current American Cancer Society guidehnes and issues in cancer screening.CA Cancer J Clin,2011,61:8-30.
  • 4Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010.CA Cancer J Clin,2010,60:277-300.
  • 5Laderach D,Movassagh M,Johnson A,et al.4-1BB co-stimulation enhances human CD8 (+) T cell priming by augmenting the proliferation and survival of effector CD8 (+) T cells.Int Immunol,2002,14:1155-1167.
  • 6Hayden PJ,Keogh F,Ni Conghaile M,et al.A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase.Bone Marrow Transplant,2004,34:545-556.
  • 7Cook R.Economic and clinical impact of multiple myeloma to managed care.J Manag Care Pharm,2008,14:19-25.
  • 8Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity [J]. J Exp Med, 1991,174(1) : 139 -149.
  • 9Linn YC, Hui KM. Cytokine-induced NK-like T cells : from bench to bedside[J/OL]. J Biomed Biotechnol, 2010, 2010: 435745.
  • 10Mcnutt M. Cancer immtmotherapy[J]. Science, 2013, 342 (6165) : 1417.

共引文献18

同被引文献35

  • 1Yu KD, Di GH, Wu J, et al. Development and trends of surgical modalities for breast cancer in China: a review of 16-year data[ J]. Ann Surg Oncol, 2007, 14 ( 9 ) : 2502-2509. DOI: 10. 1245/ s10434-007 -9436-2.
  • 2Blarney RW, Hornmark-Stenstam B, Ball G, et al. ONCOPOOL - a European database for 16,944 cases of breast cancer[ J]. Eur J Cancer, 2010,46 ( 1 ) : 56-71. DOI: 10. 1016/j. ejea. 2009. 09. 009.
  • 3Allred DC, Harvey JM, Berardo M, et al. Prognostic and predic- tire factors in breast cancer by analysis [ J ] Mod Pathol, 1998,1 1 (2) : 155-168.
  • 4Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor sta- tus by immunohistochemistry is superior to the ligand-blnding assay for predicting response to adjuvant endocrine therapy in breast cancer[J]. J CIin Oncal, 1999,17(5) :1474-1481.
  • 5Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/eollege of american pathologists guideline recom- mendations for immunohistochemical testing of estrogen and progesterone receptors in breast eaneer[ J]. J Oncol Pract, 2010,6(4) :195-197. DOI: 10. 1043/1543-2165-134.7. e48.
  • 6Simmons C, Miller N, Geddie W, et al. Does confirmatoly tumor biopsy alter the management of breast cancer patients with distant metastases [J]. Ann Oncol, 2009,20(9) :1499-1504. DOI: 10. 1093/annonc/mdp028.
  • 7Amir E, Clemons M, Purdie CA, et al. Tissue confirmation of disease recmxence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies [ J]. Cancer Treat Rev, 2012,38(6) :708-714. DOI: 10.1016/j. ctrv. 2011. 11. 006.
  • 8Yao ZX, Lu LJ, Wang R J, et al. Discordance and clinical signifi- cance of ER, PR, and HER2 status between primary bleast cancer and synchronous axillay lymph node metastasis [ J ]. Med Oncol, 2014,31 ( 1 ) :798. DOI: 10. 1007/s120324)13798-y.
  • 9Genfignani ML, Patil S, Seshan VE, et al. Feasibility and pre- dictability of perioperative PET and estrogen receptor ligand in patientswith invasive breast cancer [ J]. J Nucl Med, 2013, 54(10) : 1697-1702. DOI: 10. 2967/jnnmed. 112.113373.
  • 10Fowler AM, Chan SR, Sharp TL, et al. Small-animal PET of ster- oid hormone receptors predicts tumor response to endocrine thera- pyusing a preclinical model of breast cancer [ J ]. J Nucl Med, 2012,53 (7) : 1119-1126. DOI: 10. 2967/jnumed. 112. 103465.

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部